


SARS-COV-2 BIOMATERIALS AND ASSAY SERVICES



Your trusted virology CRO partner

Microbiologics has been creating confidence in science for more than 50 years. We are the world's leading experts and go-to collaborators in designing and producing biomaterials of all types that support assay development, drug and vaccine research, infectious disease diagnostics and beyond. With a team of highly experienced virologists and multiple BSL-3 laboratories, we are proud to provide a wide range of SARS-CoV-2 biomaterials and assay services.



High Titer Viral Stocks

We offer the highest-titer SARS-CoV-2 viral stock biomaterials on the market. We continuously source and produce variants that are clinically and diagnostically relevant for monitoring immunological responses to vaccines, measuring PCR signal detection, and performing other research. Our virus stocks are fully customizable and can be provided in infectious or inactivated formats. Our virus inactivation method is validated for added quality assurance. We provide a copy number with all materials for added convenience. Additionally, next generation sequencing (NGS) is available as an added option to ensure mutations of interest are conserved. See the reverse side for a complete list of SARS-CoV-2 isolates available.

Microneutralization Assay

We offer a high-throughput, validated, ELISA-based Microneutralization Assay for SARS-CoV-2 virus* for determining MN50 titers of sera tested against the WT SARS-CoV-2 WA-1/2020 virus. We can also develop custom microneutralization assays for additional SARS-CoV-2 variants, Influenza, and many other viruses.

Antiviral Testing

With multiple BSL-3 laboratories, we offer a variety of antiviral testing services for all available SARS-CoV-2 variants. We can test your antivirals using advanced 3D cell system models. We can also perform studies to look for escape mutants with your antiviral or therapeutic. In these experiments a sequencing report is generated listing the genetic profile of viral genomes using NGS.

*Microbiologics is a licensed service provider of this Assay through the Battelle Memorial Institute.



Microbiologics is compliant to GMP Quality System Regulation 21 CFR 820. Microbiologics is compliant to GLP Regulation 21 CFR 58.

SARS-CoV-2 Variants for Research

We provide a range of high-titer, inactivated whole virus biomaterials for SARS-CoV-2 research. Available isolates are listed below.

SARS-CoV-2 Isolate	Pango Lineage	WHO Label
hCoV-19/USA/WA1/2020	A	N/A
hCoV-19/Hong Kong/VM20001061/2020	A	N/A
hCoV-2/Italy-INMI1	No lineage only identified as Clade "O"	N/A
hCoV-2/USA-CA3/2020	B	N/A
hCoV-2/USA-CA4/2020	B	N/A
hCoV-2/USA-WI1/2020	B	N/A
hCoV-2/Germany/BavPat1/2020	B	N/A
hCoV-19/MBL-MA1/2020	B.1	N/A
hCoV-19/USA/CA_CDC_5574/2020	B.1.1.7	Alpha
hCoV-2/England/204820464/2020	B.1.1.7	Alpha
hCoV-2/South Africa/KRISP-EC-K005321/2020	B.1.351	Beta
hCoV-2/South Africa/KRISP-EC-K005325/2020	B.1.351	Beta
hCoV-19/USA/MD-HP01542/2021	B.1.351	Beta
hCoV-2/Japan/TY7-503/2021**	P.1	Gamma
hCoV-2/USA/CA/VRLC009/2021	B.1.427	Epsilon
hCoV-2/USA/CA/VRLC014/2021	B.1.429	Epsilon
hCoV-19/USA/PHC658/2021	B.1.617.2	Delta
hCoV-19/USA/MD-HP05285/2021	B.1.617.2	Delta
hCoV-19/USA/CA-VRLC086/2021	AY.1	Delta
hCoV-19/USA/MD-HP05285/2021	AY.24	Delta
hCoV-19/USA/VA-FBCH_675/2021	AY4.2	Delta
hCoV-2/Peru/un-CDC-2-4069945/2021	C.37	Lambda
hCoV-19/USA/MD-HP20874/2021	B.1.1.529, BA.1	Omicron
hCoV-19/USA/CO-CDPHE-2102544747/2021	B.1.1.529, BA.2	Omicron
hCoV-19/USA/NY-MSHSPSP-PV56475/2022	B.1.1.529, BA.2.12.1	Omicron
hCoV-19/Japan/TY41-716/2022	B.1.1.529, BA.2.75	Omicron
hCoV-19/USA/MD-HP30386/2022	B.1.1.529, BA.4	Omicron
hCoV-19/USA/MD-HP35538/2022	B.1.1.529, BA.4.6	Omicron
hCoV-19/South Africa/CERI-KRISP-K040013/2022	B.1.1.529, BA.5	Omicron
hCoV-19/USA/COR-22-063113/2022	B.1.1.529, BA.5	Omicron
hCoV-19/USA/MD-HP34985/2022	B.1.1.529, BF.5 (BA.5 like)	Omicron
hCoV-19/USA/MD-HP38288/2022	B.1.1.529, BF.7	Omicron
hCoV-19/USA/MD-HP38861/2022	B.1.1.529, BQ.1.1	Omicron
hCoV-19/USA/CA-Stanford-109_S21/2022	B.1.1.529, XBB	Omicron
hCoV-19/USA/MD-HP40900/2022	B.1.1.529, XBB.1.5	Omicron
hCoV-19/USA/MD-HP41275/2022	B.1.1.529, CH.1.1	Omicron
hCoV-19/USA/CA-Stanford-139_S23/2023	B.1.1.529, XBB.1.16	Omicron
hCoV-19/USA/New York/PV96109/2023	B.1.1.529, JN.1	Omicron

**This reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/Japan/TY7-503/2021(Brazil P.1), NR-54982, contributed by National Institute of Infectious Diseases.